Announced
Synopsis
KELIX bio, an operator of a biopharmaceutical platform, agreed to acquire Pharmaceutical Institute, a pharmaceutical company established in Rabat, from $120m. “PHI is a high-quality pharmaceutical manufacturer that has built its reputation over three decades thanks to the values of the Sedrati family. The company has earned its unique position through an outstanding record of execution and a relentless focus on quality. We are privileged to have reached an agreement with the founders and look forward to welcoming them to KELIX bio,” Hocine Sidi-Said, KELIX bio CEO.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.